SCHEMBL2395571

SCHEMBL2395571

CS(=O)(=O)c1ccc(C=O)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
ALDH1A3 P47895 3/20 0.44
ALDH3A1 P30838 2/20 0.44
VCAM1 P19320 1/20 0.41
HSD17B10 Q99714 1/20 0.40
PTGS2 P35354 2/20 0.39
TSHR P16473 1/20 0.37
TYR P14679 1/20 0.36
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CCR2 P41597 1/20 0.36
CYP2A6 P11509 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
GRM4 Q14833 1/20 0.35
PTGER4 P35408 1/20 0.35
TTR P02766 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25229335 0.98 ALDH1A1 (0.53) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL6212368 0.85 ALDH1A1 (0.55) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL7189747 0.82 ALDH1A1 (0.57) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL3324475 0.81 ALDH1A1 (0.52) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL11374196 0.81 ALDH1A1 (0.55) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL13044803 0.81 ALDH1A1 (0.55) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL3240034 0.80 ALDH1A1 (0.50) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL21773462 0.80 ALDH1A1 (0.50) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
Water SCHEMBL10953352 0.79 ALDH1A1 (0.53) ALDH1A1ALDH1A3ALDH3A1VCAM1HSD17B10
SCHEMBL6364244 0.78 L3MBTL1 (0.55) ALDH1A1ALDH1A3HSD17B10PTGS2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001049660-A1 A PROCESS FOR PREPARING 3-{[3-CHLORO-4-(METHYLSULFONYL)-PHENYL]METHYLENE}-2,4-PENTANEDIONE ORION CORPORATION (FI) 2001-07-12 WO claimed
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-02-20 US disclosed
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
US-10717734-B2 Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof PHARMAXIS LTD. (AU) 2020-07-21 US disclosed
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
CN-110709385-A Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof 法玛西斯有限公司 2020-01-17 CN disclosed
US-20190119269-A1 INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2019-04-25 US disclosed
WO-2018157190-A9 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-10-25 WO disclosed
CN-1780832-A 5-phenylthiazole derivatives and their use as PI3 kinase inhibitors NOVARTIS AG (CH) 2006-05-31 CN disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists KOSOGOF CHRISTI (US) 2005-08-04 US disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed
EP-1091933-B1 SUBSTITUTED BETA-DIKETONES AND THEIR USE ORION CORP (FI) 2003-11-26 EP disclosed
WO-2001049660-A1 A PROCESS FOR PREPARING 3-{[3-CHLORO-4-(METHYLSULFONYL)-PHENYL]METHYLENE}-2,4-PENTANEDIONE ORION CORPORATION (FI) 2001-07-12 WO disclosed
WO-2001049660-A1 A PROCESS FOR PREPARING 3-{[3-CHLORO-4-(METHYLSULFONYL)-PHENYL]METHYLENE}-2,4-PENTANEDIONE ORION CORPORATION (FI) 2001-07-12 WO disclosed
EP-1091933-A1 SUBSTITUTED $g(b)-DIKETONES AND THEIR USE ORION CORPORATION (FI) 2001-04-18 EP disclosed
US-6201027-B1 NONSTEROIDAL ANTIINFLAMMATORY DRUG FOR PROPHYLAXIS AND TREATMENT OF RESPIRATORY SYSTEM DISORDERS, I.E. ASTHMA, IN STEROID-RESISTANT MAMMALS ORION CORPORATION (FI) 2001-03-13 US disclosed
WO-2000001667-A1 SUBSTITUTED β-DIKETONES AND THEIR USE ORION CORPORATION (FI) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 ALDH1A1 2435/4885ALDH1A3 2985/4885ALDH3A1 1667/4885
US-10717734-B2 Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof IDO1, IDO2, INMT ALDH1A1 322/4885ALDH1A3 979/4885ALDH3A1 211/4885
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF SULT1E1, TPMT, SULT1A1 ALDH1A1 211/4885ALDH1A3 743/4885ALDH3A1 777/4885
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF LOX, DAO, AADAC ALDH1A1 301/4885ALDH1A3 858/4885ALDH3A1 135/4885
US-20190119269-A1 INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF IDO1, IDO2, INMT ALDH1A1 322/4885ALDH1A3 979/4885ALDH3A1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.